ArchivesMagazine - 20 Nov 2014Premaitha eyes genetic test Pre-natal screening company is waiting on regulatory approval 20 November 2014|Small Caps Issue: 20 Nov 2014 - Page 38 < Best & Worst Performing Small Caps Table R&D capitalising controversy > Issue: 20 Nov 2014 - Page 38 | Contents Next: R&D capitalising controversy Previous: Best & Worst Performing Small Caps Table Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. Mark Dunne Issue Contents Chartist British brands in focus Cover Story Charge ahead Databank The Best & Worst Performers: FTSE 350, Global Market, Commodities, Forex, Sovereign Yields Diary Preview: Netcall Director Deals Director Dealings: Top buys and sells Flybe cleared for take-off Under the microscope Feature New ventures, new horizons Sleep at night investments Forex Euro sparks into life Sterling on the slide Funds Profit from mighty oaks Griller Premier's balancing act News News in brief: Tracsis, Quintain, Salamander, IG, Haliburton, Volex, Red24, James Fisher Reckitt to float drugs arm Go with the Scapa flow Don’t bank on Virgin Money House prices on shaky ground Carnival’s slick move India’s corporate boost Opinion Keep a watching eye Plays Plays update: Prudential Plays update: Telit Communications Plays update: Diploma Plus500 powers on Plays update: Redcentric Cambria is in top gear Sector Reports Still on the defensive Small Caps Best & Worst Performing Small Caps Table Strat Aero’s drone push Premaitha eyes genetic test Creston’s joined up thinking The Big Debate R&D capitalising controversy Under The Bonnet Pay closer attention
